Search - tctmd.com

Displaying 381 - 400 of 764

Sort: Relevancy | Date

News Daily News

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Salynn Boyles

December 15, 2014

Presentation

Stent Coverage and Neointimal Proliferation in BMS Postdilated With a Paclitaxel-Eluting Balloon vs EES

Presenter: T.C. Poerner

December 14, 2014

News Daily News

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

December 14, 2014

News Conference News AHA 2014

Long-Term Better than Short-Term Prasugrel After PES Stenting

November 15, 2014

News Daily News

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

Caitlin E. Cox

October 24, 2014

News Daily News

DCB在原发性病变中的表现比在再狭窄股腘动脉病变中更好

Caitlin E. Cox

October 24, 2014

News Daily News

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Caitlin E. Cox

October 24, 2014

News Industry News

The Lutonix® 035 Drug Coated Balloon is the First and Only FDA-Approved DCB Available in the U.S. for the Treatment of Femoropopliteal Occlusive Disease

October 10, 2014

News Daily News

Los Balones liberadores de Fármacos Fracasan en el Manejo de Lesiones por Debajo de la Rodilla en Pacientes con Isquemia Crítica de las Extremidades

Todd Neale

October 10, 2014

News Daily News

Drug-Eluting Balloon Fails for Below-the-Knee Lesions in Critical Limb Ischemia Patients

Todd Neale

October 10, 2014

News Daily News

Subestudio del HORIZONS-AMI: Las Mujeres Corren Más Riego Hemorrágico Post-STEMI

Yael L. Maxwell

October 03, 2014

News Daily News

HORIZONS-AMI Substudy: Women at Higher Risk for Bleeding After STEMI

Yael L. Maxwell

October 03, 2014

Presentation TCT 2014

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Freek Nijhoff

September 16, 2014

Presentation TCT 2014

Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use of Drug Coated Balloon Catheters

Presenter: Charisse Ward

September 16, 2014

Presentation TCT 2014

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

Presenter: Georgios Vlachojannis

September 16, 2014

Presentation TCT 2014

New Ultrasound Enhanced Paclitaxel Therapy to Treat Critical Limb Ischemia

Presenter: Chaim S. Lotan, Julio C. Palmaz, Mark A. Turco, Roberto Gandini

September 15, 2014

News Conference News TCT 2014

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

September 15, 2014

News Conference News TCT 2014

Keynote Address Focuses on Newer DES, Problematic Subgroups

September 15, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

Presentation TCT 2014

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

Presenter: Run-Lin Gao, Jochen Wöhrle, Bruno Scheller, Yelin Zhao

September 13, 2014

Advertisement

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Stent Coverage and Neointimal Proliferation in BMS Postdilated With a Paclitaxel-Eluting Balloon vs EES

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

Long-Term Better than Short-Term Prasugrel After PES Stenting

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

DCB在原发性病变中的表现比在再狭窄股腘动脉病变中更好

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

The Lutonix® 035 Drug Coated Balloon is the First and Only FDA-Approved DCB Available in the U.S. for the Treatment of Femoropopliteal Occlusive Disease

Los Balones liberadores de Fármacos Fracasan en el Manejo de Lesiones por Debajo de la Rodilla en Pacientes con Isquemia Crítica de las Extremidades

Drug-Eluting Balloon Fails for Below-the-Knee Lesions in Critical Limb Ischemia Patients

Subestudio del HORIZONS-AMI: Las Mujeres Corren Más Riego Hemorrágico Post-STEMI

HORIZONS-AMI Substudy: Women at Higher Risk for Bleeding After STEMI

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use of Drug Coated Balloon Catheters

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

New Ultrasound Enhanced Paclitaxel Therapy to Treat Critical Limb Ischemia

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

Keynote Address Focuses on Newer DES, Problematic Subgroups

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content